Chronic kidney disease (CKD) disproportionately affects minority populations in the United States, with age-standardized CKD prevalence rates in Black populations being 2 times higher than in White populations (Black, 19.9% [95% confidence interval (CI), 10.2%-13.7%]; White, 11.9 % [95% CI, 10.2%-13.7%]).1 Health disparities persist in vascular access creation, with Black and Hispanic patients being 10%-28% less likely to initiate hemodialysis with an arteriovenous fistula than White patients.2 It’s expected that only 59% of incident arteriovenous fistula creations will be functionally patent at 1 year.